Side-by-side comparison of AI visibility scores, market position, and capabilities
Nautilus Biotechnology is building a single-molecule proteomics platform to map and quantify the full human proteome at a scale and sensitivity previously impossible.
Nautilus Biotechnology is a proteomics company founded in 2016 and publicly listed on Nasdaq, developing a revolutionary platform for analyzing proteins at single-molecule resolution. While genomics has transformed medicine through DNA and RNA sequencing, the proteome is the actual functional layer of biology where drug targets, disease biomarkers, and therapeutic mechanisms operate. Nautilus is building a platform that can identify and quantify thousands of proteins simultaneously from tiny biological samples using a fluorescence-based single-molecule detection approach without requiring mass spectrometry. The platform promises to enable proteomics studies at a scale and depth comparable to what next-generation sequencing delivered to genomics, unlocking new insights into disease biology and drug development. Nautilus is in the instrument development phase and targets pharmaceutical research, clinical diagnostics, and academic biology. The company has raised over $250M and is building manufacturing capabilities for a planned commercial instrument launch that could define a new era in proteomics research.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.